Gleevec Extends Post-Surgery GIST Survival Significantly; Wins Full Adjuvant Approval
By
Shirley Haley / Email the Author / “The Pink Sheet” DAILY Feb. 1, 2012
Word Count: 647 / Article # 14120201006
Executive Summary
Patients who took Novartis’ Gleevec for three years after surgery to remove gastrointestinal stromal tumors had a 54% reduction in risk of recurrence and a 55% reduction in risk of death compared to patients who took it for only one year.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.